Aegis Capital reiterated coverage on Cidara Therapeutics with a new price target

9/22/21 12:28:31 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Aegis Capital reiterated coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $8.00 from $9.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CDTX

Date	Price Target	Rating	Analyst
6/18/2025	$41.00	Buy	H.C. Wainwright
3/12/2025	$46.00	Mkt Outperform	Citizens JMP
1/27/2025		Overweight	Cantor Fitzgerald
12/13/2024	$34.00	Outperform	RBC Capital Mkts
11/8/2024	$33.00	Buy	Guggenheim
8/14/2024	$24.00	Neutral → Buy	H.C. Wainwright
12/3/2021	$6.00	Buy	H.C. Wainwright
9/22/2021	$9.00 → $8.00	Buy	Aegis Capital